Arrowhead Pharmaceuticals (ARWR) Projected to Post Earnings on Tuesday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is expected to post its Q3 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to announce earnings of ($1.28) per share and revenue of $44.1730 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.17. The company had revenue of $73.74 million during the quarter, compared to analyst estimates of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.Arrowhead Pharmaceuticals’s revenue was down 86.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.75 earnings per share. On average, analysts expect Arrowhead Pharmaceuticals to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arrowhead Pharmaceuticals Stock Down 3.1%

ARWR stock opened at $84.65 on Friday. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 1.41. Arrowhead Pharmaceuticals has a 1-year low of $15.01 and a 1-year high of $95.49. The stock has a market cap of $11.92 billion, a price-to-earnings ratio of -39.37 and a beta of 1.26. The company’s 50 day moving average is $79.04 and its 200 day moving average is $70.67.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Piper Sandler restated an “overweight” rating and set a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research report on Thursday, July 23rd. Stifel Nicolaus began coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They issued a “buy” rating and a $98.00 target price for the company. JPMorgan Chase & Co. increased their target price on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Sanford C. Bernstein raised their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Finally, B. Riley Financial lifted their price target on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a “buy” rating in a research note on Thursday. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $96.92.

Insider Activity at Arrowhead Pharmaceuticals

In related news, Director Hongbo Lu sold 2,970 shares of Arrowhead Pharmaceuticals stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total value of $228,333.60. Following the transaction, the director directly owned 52,012 shares of the company’s stock, valued at $3,998,682.56. The trade was a 5.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in ARWR. Invesco Ltd. raised its stake in shares of Arrowhead Pharmaceuticals by 8.9% during the fourth quarter. Invesco Ltd. now owns 547,758 shares of the biotechnology company’s stock valued at $36,366,000 after acquiring an additional 44,866 shares during the last quarter. Corient Private Wealth LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 3.1% during the fourth quarter. Corient Private Wealth LLC now owns 18,226 shares of the biotechnology company’s stock worth $1,210,000 after purchasing an additional 551 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth about $352,000. Summit Global Investments grew its stake in shares of Arrowhead Pharmaceuticals by 43.8% in the fourth quarter. Summit Global Investments now owns 14,287 shares of the biotechnology company’s stock worth $949,000 after purchasing an additional 4,353 shares during the last quarter. Finally, State of Tennessee Department of Treasury increased its holdings in Arrowhead Pharmaceuticals by 2.0% during the 4th quarter. State of Tennessee Department of Treasury now owns 55,642 shares of the biotechnology company’s stock valued at $3,858,000 after purchasing an additional 1,092 shares during the period. Institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.